Trade

with

Protalix BioTherapeutics Inc
(Amex: PLX)
AdChoices
2.30
-0.06
-2.54%
After Hours :
-
-
-

Open

2.36

Previous Close

2.36

Volume (Avg)

244.54k (451.43k)

Day's Range

2.30-2.48

52Wk Range

2.05-5.30

Market Cap.

215.43M

Dividend Rate ( Yield )

-

Beta

0.85

Shares Outstanding

93.66M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 11.51M

    • Net Income

    • -27.79M

    • Market Cap.

    • 215.43M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -206.85

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 0.85

    • Forward P/E

    • -

    • Price/Sales

    • 15.02

    • Price/Book Value

    • -5.56

    • Price/Cash flow

    • -7.86

      • EBITDA

      • -23.58M

      • Return on Capital %

      • -37.87

      • Return on Equity %

      • -

      • Return on Assets %

      • -37.87

      • Book Value/Share

      • -0.42

      • Shares Outstanding

      • 93.66M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 6.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -0.17

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -12.30

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 39.40

            • 82.75

            • Pre-Tax Margin

            • -206.85

            • 39.38

            • Net Profit Margin

            • -206.85

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 214.00

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -1,850.00

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 3.03

              • 2.92

              • Quick Ratio

              • 2.69

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -0.42

              • 4.75

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -7.26

                • 277.78

                • P/E Ratio 5-Year High

                • -38.47

                • 634.30

                • P/E Ratio 5-Year Low

                • -6.31

                • 124.82

                • Price/Sales Ratio

                • 15.02

                • 9.35

                • Price/Book Value

                • -5.56

                • 8.50

                • Price/Cash Flow Ratio

                • -7.86

                • 50.25

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -37.87

                        (-37.40)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • 1.23

                      • 1.48

                      • Asset Turnover

                      • 0.18

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -27.12M
                      Operating Margin
                      -235.53
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -7.86
                      Ownership

                      Institutional Ownership

                      63.95%

                      Top 10 Institutions

                      55.50%

                      Mutual Fund Ownership

                      19.32%

                      Float

                      83.99%

                      5% / Insider Ownership

                      4.50%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Federated Kaufmann Fund

                      •  

                        7,325,197

                      • 0.00

                      • 7.83

                      • Allianz Biotechnologie

                      •  

                        2,142,105

                      • -56.35

                      • 2.45

                      • Federated Kaufmann Small Cap Fund

                      •  

                        1,168,970

                      • -11.87

                      • 1.25

                      • BlackRock Health Sciences Opps Port

                      •  

                        1,155,326

                      • 0.00

                      • 1.23

                      • AST Federated Aggressive Growth

                      •  

                        1,055,300

                      • 0.00

                      • 1.13

                      • Fidelity® Select Biotechnology Portfolio

                      •  

                        975,842

                      • 0.00

                      • 1.04

                      • ZI BlackRock Global Fds Wld Health Sci

                      •  

                        437,574

                      • 0.00

                      • 0.47

                      • I.B.I Tel Aviv 75 Basket

                      •  

                        248,050

                      • -4.99

                      • 0.27

                      • Harbor International Growth Fund

                      •  

                        245,344

                      • 19.48

                      • 0.26

                      • FCP OP MEDICAL BioHealthTrends

                      •  

                        224,924

                      • 46.13

                      • 0.24

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Federated Global Inv Mgmt Corp

                      •  

                        9,942,841

                      • +594.34%

                      • 10.62

                      • Baillie Gifford & Co Limited.

                      •  

                        6,407,588

                      • +8.93%

                      • 6.85

                      • Allianz Global Investors

                      •  

                        5,056,168

                      • -17.51%

                      • 5.40

                      • Allianz Global Investors U.S. LLC

                      •  

                        2,142,105

                      • -56.35%

                      • 2.45

                      • Camber Capital Management LLC

                      •  

                        2,000,000

                      • 0.00%

                      • 2.14

                      • BlackRock Advisors LLC

                      •  

                        1,794,355

                      • +0.09%

                      • 1.92

                      • Dafna Capital Management LLC

                      •  

                        1,178,440

                      • 0.00%

                      • 1.26

                      • Fidelity Management and Research Company

                      •  

                        1,066,785

                      • -6.98%

                      • 1.14

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Speculative Growth

                      Style

                      Small Growth

                      Protalix BioTherapeutics, Inc. was incorporated in Florida on April 1992. The Company and its wholly-owned subsidiary, Protalix Ltd. operate as biopharmaceutical companies focused on the development and commercialization of recombina...morent therapeutic proteins based on the Company’s proprietary ProCellEx protein expression system or ProCellEx. The Company’s product development candidate is prGCD for the treatment of Gaucher disease, which the Company is developing using its ProCellEx protein expression system. Using its ProCellEx system, it is developing a pipeline of proprietary and biosimilar or ‘generic’ versions of recombinant therapeutic proteins based on its plant cell-based expression technology that target large, established pharmaceutical markets and that rely upon known biological mechanisms o...moref action. The Company’s initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. The biotechnology and pharmaceutical industries are characterized by rapidly evolving technology and significant competition. Competition from numerous existing companies and others entering the fields in which it operates is intense and expected to increase. As of December 31, 2013 the Company holds 49 patents. The testing, manufacture, distribution, advertising and marketing of drug products are subject to extensive regulation by federal, state and local governmental authorities in the United States, including the FDA, and by similar authorities in other countries.lessless

                      Key People

                      Dr. David Aviezer,PhD

                      CEO/Director/President

                      Moshe Manor

                      CEO/Director/President

                      Shlomo Yanai

                      Chairman of the Board/Director

                      Yossi Maimon

                      CFO/Chief Accounting Officer/Secretary/Treasurer/Vice President

                      Dr. Yoseph Shaaltiel,PhD

                      Director/Executive VP, Divisional

                      • Protalix BioTherapeutics Inc

                      • 2 Snunit Street

                      • Carmiel, 20100

                      • USA.Map

                      • Phone: +972 49889488

                      • Fax: -

                      • protalix.com

                      Incorporated

                      1992

                      Employees

                      260

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: